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Bacterial toxin inhibitors based on multivalent
scaffolds†
Thomas R. Branson and W. Bruce Turnbull*
Protein toxins released by certain intestinal bacteria are the cause of many diarrhoeal diseases including
cholera and travellers’ diarrhoea. The toxins enter their target cells by first binding to specific glycolipids
in the cell membrane. Inhibition of these protein–carbohydrate interactions has the potential to prevent
the toxins from reaching their site of action, and thus avoid the ensuing diarrhoea. Simple
oligosaccharides typically have low aﬃnities for the protein toxins, therefore inhibitor design has
focussed on exploiting the principles of multivalency: multiple weak interactions acting in concert can
enhance the overall binding interaction. The major classes of multivalent inhibitors investigated to date
will be discussed; these include glycopolymers, glycodendrimers, tailored glycoclusters and inhibitors
exploiting templated assembly.
Key learning points
1 Benefits of multivalent over monovalent inhibitors for bacterial toxins.
2 Overview of diﬀerent types of multivalent scaﬀolds for constructing inhibitors.
3 The influence of ligand density on the activity of multivalent inhibitors.
4 The potential benefits of tailor-made inhibitor scaﬀolds.
5 The use of ligand templating for pre-organising inhibitor structures.
Introduction
Diarrhoeal diseases continue to pose a serious threat to human
health, with an estimated two million deaths per annum, most of
which are in children under five years old.1 A significant portion of
these cases can be attributed to bacteria that produce protein toxins.
The most widely studied of these toxins are cholera toxin (CT), the
closely related E. coli heat-labile toxin (LT)2,3 and shiga-like toxin
(Stx; also known as verotoxin, VT).4 Together, they belong to a family
of AB5 toxins that comprise a single toxic A-subunit that is
associated with a non-toxic B-pentamer that is a carbohydrate-
binding protein which enables the toxin to enter cells (Fig. 1a).5,6
Following initial adhesion of the B-pentamer to specific glycoli-
pids that are present on the surface of the cells that line the
intestine, the toxins enter the cells by endocytosis. They are then
transported through the cell to the endoplasmic reticulumwhere the
toxic A-subunit is released into the cytosol to have its cytotoxic
eﬀect.7,8 In the case of CT and LT, the toxin ADP-ribosylates the Gsa
protein which leads to a rise in cAMP concentration in the cell and a
complex series of events that result in release of water into the
intestine.2 In the case of Stx, the toxic A-subunit is an N-glycosidase
that removes purine bases from ribosomal RNA, thus inhibiting
protein synthesis and causing cell death.9
The structures of the B-subunits of cholera and heat-labile
toxins (CTB and LTB) are 80% identical, but they share essen-
tially no sequence homology with the shiga-like toxin B-subunit
(StxB) (Fig. 1b–c).5 This observation is surprising as all three
toxins have the same protein fold and have evolved to perform
the same function, i.e., to enable toxin endocytosis by binding
to cell surface glycolipids. This function is facilitated by having
their glycolipid binding sites arranged on the same face of the
protein so that they can engage multiple copies of the sugar
ligands at the same time.
The similarities and diﬀerences in protein sequences of
CTB, LTB and StxB are reflected in their carbohydrate-binding
specificities. CTB and LTB both recognise ganglioside GM1 1,10
while StxB binds to globotriaosyl ceramide (Gb3) 2 (Fig. 1).
11
However, CTB and LTB are not identical, and certain variants
of these proteins can diﬀerentiate between blood group oligo-
saccharides in a secondary binding site on the circumference of
the pentamer.12–14 The most striking diﬀerence between CTB/
LTB and StxB lies in the aﬃnities for their glycolipid ligands.
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The CTB/LTB-GM1 interaction is among the highest aﬃnity
protein–carbohydrate interactions known (Kd = 10–40 nM for a
monovalent interaction),15 whereas StxB binds only weakly to
individual Gb3 oligosaccharides (Kd = 1 mM).
16 Therefore, StxB
relies on multivalency (i.e., simultaneous binding to multiple
copies of its ligand) to achieve a functionally useful interaction
with a cell surface. Up to 15 copies of the Gb3 ligand can bind
simultaneously to a StxB pentamer leading to a sub-nM dis-
sociation constant.11 Although CTB/LTB can bind tightly to an
individual GM1 molecule, multivalent interactions are still
important in facilitating endocytosis.17
As protein–carbohydrate interactions are an essential pre-
requisite for cell entry and toxin activity, the development of
inhibitors for these interactions has attracted much interest
over recent years. In general it is very challenging to make low
weight inhibitors of carbohydrate-binding proteins as the bind-
ing sites are typically shallow and highly solvated. In the case of
CTB/LTB, substantial changes to the GM1 structure usually
result in decreases in aﬃnity (Fig. 2).18 For example, methyl
b-galactoside 3 has a 15mMdissociation constant;15GM1mimic
4 has a Kd value of 10 mM;
19 and aromatic a-galactosides 5 and 6
have Kd values of 125 and 12 mM, respectively.
20 As even the best
of these compounds still bind around 1000 times more weakly
than GM1 1, researchers have instead focussed their attention
on making multivalent inhibitors that can engage multiple
carbohydrate binding sites simultaneously. Herein we will
compare some of the major classes of multivalent inhibitors
investigated to date: glycopolymers, glycodendrimers, tailored
glycoclusters and inhibitors exploiting templated assembly (Fig. 3).
Polymeric inhibitors
To take advantage of the benefits of multivalency, a suitable
method must be found to connect multiple ligands together.
The most simple way to organise multiple copies of a ligand is
to string them out along a chain. Polymers can be used to
achieve this arrangement; their relative ease of synthesis and
variability of structure and length make them ideal for use as a
general architecture for multivalent presentation.
The benefits of using multivalent inhibitors for bacterial toxins
were shown in an early example by Schengrund and Ringler.21 In
this study, reductive amination of the GM1os to the free amino
groups on the polylysine scaﬀold resulted in polymer 7 (Fig. 4) with
an average of eight oligosaccharides. It was found that this polymer
was 1000-fold more eﬀective than GM1 oligosaccharide for inhibit-
ing cholera toxin from adhering to GM1 coated plates.
Gb3–polyacrylamide conjugates have been used to neutralise
Stx-1 in human ACHN cells by Dohi et al.22 They concluded that
the clustering eﬀect of multiple ligands presented on polymer 8
must be the reason for successful inhibition as the individual
aﬃnity of one copy of the Gb3 ligand was too low to have any
eﬀect in cells. Analogous polyacrylamide glycopolymers having
varying degrees of substitution with the Gb3 trisaccharide were
reported by Gargano et al.23 They found that polymer 9 gave
5000 times enhancement of the inhibition of Stx-1 over the
monomeric carbohydrate. The degree of ligand substitution
between 10% and 30% did not have a substantial eﬀect on
inhibition. In contrast, other studies with similar polymers
have shown that the density of the carbohydrate ligands on
the polymer chain can aﬀect the binding aﬃnity to the Stx-2
isoform of the toxin, as can the length of spacer from the
backbone chain.24,25 For example, a higher density of Gb3 along
polymer chain 10 provided higher aﬃnity binding to Stx-2 but
had little eﬀect on binding to Stx-1.24 The density-dependence
of binding to Stx-2 is significant as the Stx-2 isoform of the toxin
is considered to have greater clinical importance than Stx-1.
The Kiick group have extensively investigated the eﬀect on
inhibition by carbohydrate density; the specific distance
between carbohydrates on a polypeptide chain; and the spacer
length from the polypeptide backbone. Using galactosyl
Thomas R. Branson
Tom Branson was born in Derby,
England in 1987. He graduated
from the University of York in
2009 with a Master of Chemistry
degree, having spent his final year
studying at The University of
Helsinki. He is currently working
for a PhD in the Turnbull
laboratory at The University of
Leeds. His current research
focuses on the design and
creation of protein architectures
via protein–carbohydrate inter-
actions and the synthesis of multi-
valent cholera toxin inhibitors.
W. Bruce Turnbull
Bruce Turnbull gained his BSc
from the University of St
Andrews in 1995, where he
stayed on to study for a PhD
with Prof. Rob Field. He then
held a Wellcome Trust
International Prize Travelling
Research Fellowship with Prof.
Sir Fraser Stoddart at the
University of California, Los
Angeles and with Prof. Steve
Homans at the University of
Leeds. Since 2005, he has been
a Royal Society University
Research Fellow in the School of Chemistry, University of Leeds.
His research interests include oligosaccharide synthesis,
protein–carbohydrate interactions and their potential
application in synthetic biology. He chairs a COST Action
network on Multivalent Glycosystems for Nanoscience.
Tutorial Review Chem Soc Rev
D
ow
nl
oa
de
d 
on
 1
3/
05
/2
01
3 
19
:0
0:
50
. O
pe
n 
A
cc
es
s A
rti
cl
e.
Pu
bl
ish
ed
 o
n 
21
 D
ec
em
be
r 2
01
2 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C2
CS
354
30F
View Article Online
This journal is c The Royal Society of Chemistry 2013 Chem. Soc. Rev., 2013, 42, 4613--4622 4615
polymers 11 and 12 as inhibitors for CTB, it was found that as
the density of ligands increases, so the inhibitory eﬀect
decreases.26 These results are in contrast to the previous
findings by Watanabe et al. with Stx-2.24 Kiick and co-workers
concluded that the best inhibition was achieved when the
spacing between ligands on the polymer chain was matched
to the distance between binding pockets of the toxin; this
distance being 35 Å for CTB. When the density was suﬃciently
high that spacing between carbohydrates was smaller than the
distance between binding sites, steric hindrance created by
unbound ligands decreased overall binding. The spacer length
from the polymer backbone chain told a similar story.26
Inhibition was greater when the spacer matched the natural
ligand length of GM1 (16 Å). The longer ligand 12 could
therefore fully penetrate the binding site as opposed to a
reduced accessibility when a shorter spacer 11 was used.
Matching the ligand spacing to the binding site dimensions
improves the eﬀectiveness of the ligands, giving rise to high
inhibition with these well designed polymers.
Richards et al. had similar findings with their polymetha-
crylamide polymers 13 presenting galactosyl ligands for CTB
binding.27 This study went further to suggest that there is a
varying relationship between ligand density and inhibition. At a
high density of carbohydrates along the polymer chain, a high
rate of statistical rebinding is achieved giving good inhibition.
At only 10% density there is lower steric hindrance and a better
fit to the binding site. Similar inhibition results were found per
galactose moiety for polymers substituted 100% and 10% with
ligand groups. Between these values, inhibition decreases as
the balance between the competing eﬀects worsens.
Further studies were performed by the Kiick group on the
composition of polypeptide backbones. They found that
random coil backbones were better suited than those with
restricted alpha helical conformations, as flexibility of the
polymers allows more accessible ligand groups.28 They showed
that electrostatic repulsion gave a larger hydrodynamic radius
for a polymer with negatively charged residues than for a
neutral chain.29 The resulting larger chain dimensions led to
better inhibition, again due to the accessibility of the ligands.
The charge of the peptide backbone was also shown to be of
importance as negative glutamic acid residues aided inhibition,
neutral glycine residues were acceptable, but positively charged
lysine residues were detrimental to the inhibitory properties of
the glycopolymers.30 There are positively charged residues
Fig. 1 (a) Cholera toxin (1S5F.pdb); (b) cholera toxin B-pentamer (CTB) with GM1
ligand 1 depicted as a stick structure (3CHB.pdb); (c) shiga-like toxin B-pentamer
(VTB/StxB) with Gb3 ligand 2 depicted as a stick structure (1BOS.pdb).
Fig. 2 Monovalent galactoside inhibitors for CTB/LTB.
Fig. 3 (a) Glycopolymer; (b) glycodendrimer; (c) glycocluster.
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present on the surface of CTB around the binding pocket and
so complementing these charges should improve binding. A
negatively charged backbone gave an IC50 value almost three
times better than that for a neutral backbone, whereas introducing
positive charges led to an IC50 value four times worse than a
neutral backbone.
Bundle and co-workers have reported a strategy to identify
optimal ligand groups for multivalent display by synthesising
libraries of glycomimetics on polyacrylamide or aminated
dextran backbones.31 They found that screening ligand groups
for CTB inhibition in a multivalent format made it easier to
identify optimal ligands than if they had studied the analogous
low aﬃnity monovalent compounds.
Without prior knowledge of the valency or structure of the
target protein, polymers are a good starting point for building
multivalent inhibitors. However, defining the distance between
ligand groups and the length of the spacer to the polymer
backbone can result in much improved binding when these
parameters can be matched with the dimensions of the protein
binding sites. While linear polymers with pendant carbo-
hydrate groups are relatively easy to make, they are also
frequently heterogeneous in their distribution of the ligand
groups. Therefore only a subset of ligand groups will presumably
be in the optimal arrangement to binding to the target protein.
Multivalent scaﬀolds that provide greater homogeneity or
restrict the ligand groups into a favourable orientation for
binding could potentially provide improved inhibition.
Branching out into glycodendrimers
Glycodendrimers are monodisperse branched tree-like
structures that, in principle, combine the advantages of homo-
geneous small molecular inhibitors with the dimensions and
high valencies of glycopolymers.32,33 Schengrund’s group was
the first to use PAMAM 14 and poly(propylene imine) 15
dendrimers for CT inhibition, building on their knowledge of
multivalent polymers.34,35 These dendrimers (Fig. 5) with an
average of seven GM1 ligands attached, provided inhibition
against CT binding to cell surfaces. The results were found to
be similar to those for their polymers and provided 1000-fold
increased inhibition relative to GM1 oligosaccharide.
The Pieters group have created a set of dendrimers, synthe-
sised by a convergent approach, with a variety of carbohydrate
end groups as CTB inhibitors (Fig. 6).36 Their first scaﬀolds
were prepared with two, four and eight arms terminating in
lactose sugars (16a–c).37 As expected, it was found that the
multivalent dendrimers gave an increase in inhibition with the
octavalent ligand having the strongest binding with a Kd of
33 mM as measured by a fluorescence titration assay. More
surprisingly however, were the results for the monovalent and
divalent ligands. The monovalent lactosyl head group had a Kd
of 248 mM, 73 times more potent than simple lactose. This
increase in aﬃnity could partially be explained by additional
interactions being created between the aglycone and the
protein. The divalent ligand 16a gave an aﬃnity only slightly
stronger and it was proposed that this was because the linker
length was not suﬃcient to allow both carbohydrates to bind
simultaneously to adjacent subunits. It is therefore important
to note that binding site spacing needs to be taken into account
when designing dendrimers for multivalent inhibition, as with
glycopolymers.
A more systematic study then followed from the same group
using the same dendrimer scaﬀold as before, but with
increased linker lengths to improve the reach of their ligands.
SPR binding studies demonstrated that dendrimers 17a–c
bearing an (R)-lactic GM1 mimic all achieved improved bind-
ing.38 The monovalent ligand had an IC50 value of 97 mM, while
that for divalent compound 17a was 13 mM. The tetra- and
octavalent inhibitors 17b and 17c both gave IC50 = 0.5 mM,
Fig. 4 Glycopolymer inhibitors of bacterial toxins.
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however, the detection limit for the assay had already been
reached. An ELISA assay confirmed the octavalent dendrimer to
be the most potent.
Galactose ligands on a long PEG spacer were also studied.39
The PEG spacer was introduced to mimic the hydrophilicity and
lipophilicity of GM1 and was introduced onto the dendrimers
via ‘‘click’’ chemistry. Divalent compound 18a had an IC50 value
of 130 mM in an ELISA assay, compared to 80 mM for the
monovalent ligand. The best dendrimer was found to give
similar activity to the natural GM1 oligosaccharide ligand. This
was octavalent ligand 18c which had an IC50 of 12 mM, i.e., 2500
times more potent per sugar group than the monovalent
galactosyl compound. The strongest inhibitory potency was
found when GM1 oligosaccharides were attached to dendritic
scaﬀolds a–c.40 Octavalent ligand 19c was found to have an IC50
of 50 pM, almost 50000 times stronger per sugar group than the
GM1 oligosaccharide.
Sisu et al. used a combination of analytical ultracentrifuga-
tion, dynamic light scattering and atomic force microscopy to
show that Pieters’ di- and tetravalent dendrimers (19a and 19b)
inhibited toxin adhesion through an aggregation mechanism.41
Some dimerisation of LTB was shown to be induced by the
divalent compounds but this was not seen for the tetravalent
compound. While the multivalent ligands could have
potentially formed discrete protein assemblies, in this case
uncontrolled aggregation was observed. It was proposed that
the random aggregation occurred as a consequence of a
mismatch between the valencies of the ligands and the toxin.
A set of carbosilane structures named ‘‘Super Twig’’ (Fig. 7)
were produced by Nishikawa et al. and used to inhibit StxB.42
The Super Twig dendrimers were synthesised in a divergent
fashion by consecutive reaction of trichlorosilane and allyl
Grignard, with the sugars then coupled to brominated terminal
groups. First generation dendrimers were produced with the
Gb3 trisaccharide appended at the termini. A compound with
six oligosaccharides 21 was found to neutralise Stx in vivo
and completely suppressed the lethal eﬀect of Stx when
administered intravenously in mice. The dendrimers were
further optimised to function in circulation and a newmolecule
with 18 carbohydrate groups 22 showed complete inhibition of
Stx-2.43 Dendrimers were synthesised with up to 36 head groups
but this large increase was not reflected with much change in
the aﬃnity for Stx as all the structures gave similar results. The
dumbbell shape of the dendrimers was found to be important as a
structure with only one group of three Gb3 ligands 20 gave a much
higher Kd of 195 mM compared to 0.69 mM when there were two
groups 21 and 0.45 mM for the second generation dendrimer 22.
The best glycodendrimers are better than the best of the
linear polymers. However, the preference for having long
flexible linkers to the ligand groups indicates that the densely
packed globular shape of higher generation dendrimers is not
desirable for inhibition. The glycodendrimers synthesised to
date do not take advantage of the 5-fold symmetry of bacterial
toxins, which suggests that further advantage could be gained
through the design of tailor-made inhibitors.
Reaching for the stars
Concurrent independent studies by Bundle44 and Fan45 led to
the creation of star-shaped inhibitors that take advantage of the
pentagonal symmetry of bacterial toxins. Theoretically, a five
armed star could sit on a toxin pentamer with each arm
reaching out to a separate binding site. While the Bundle group
focussed on inhibitors of Stx, Fan, Hol and co-workers designed
inhibitors for LT and CT.
The Fan group attached galactose onto the arms of a scaﬀold
radiating from a pentacyclen core (Fig. 8).45 They adopted a
modular approach to the design and synthesis of the linker
arms so that they could be varied in length. The use of squaric
acid diesters as linking agents allowed two diﬀerent amines to be
Fig. 5 PAMAM and poly(propylene imine) glycodendrimers.
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coupled consecutively in an eﬃcient manner. The eﬀective
length of long flexible linkers is actually much shorter than
the extended conformation and it was found that the inhibitor
was most potent when the linkers were of a size that presented
the carbohydrate ligands eﬃciently at the binding sites. This
finding confirmed the concept proposed previously by Kramer
and Karpen that matching the eﬀective dimensions of a ligand
with flexible linkers and the binding site distribution, gives the
greatest binding aﬃnity.46 The multivalent eﬀect of the optimal
pentavalent scaﬀold 23 (n = 4) gave a 100 000-fold enhancement
in the IC50 value over a monovalent galactoside. It was also
found that the pentavalent ligands formed 1 : 1 complexes with
the toxins and no large scale aggregates were observed.
Higher aﬃnity inhibitors were produced by incorporating
m-nitrophenyl-a-galactoside as the ligand group, and introducing
a guanidine-bridged water soluble linker. The resulting
compound 24 had an IC50 of 6 nM, which was about 3 times
more potent than the GM1 oligosaccharide.47
Targeting multiple copies of the toxins
When using multivalent ligands to inhibit protein binding it
has been seen that tailoring the design of the ligand can greatly
improve its binding strength. However, it could prove more
eﬃcient to be able to complex more than one toxin protein with
each inhibitor. Targeting multiple proteins at once can be
achieved by using chemical-inducers of dimerisation (CIDs).48
If the multivalency strategy were to be combined with CIDs
then self-templating, self-assembled structures could potentially
produce better inhibition of the toxins.
The Bundle group was the first to make a large step towards
this goal with their Starfish ligand 26 (Fig. 9).44 Two carbo-
hydrate ligands were arranged at the end of each arm of a
pentavalent glucose core. Starfish 26 gave over a million fold
increase in inhibition relative to the monovalent Gb3 ligand.
The decavalent structure was originally designed to bind to two
Fig. 6 Glycodendrimer inhibitors synthesised by Pieters and co-workers.
Fig. 7 Super Twig dendrimers.
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separate binding sites on each sub-unit of the shiga-like toxin.
However, a crystal structure of the complex revealed that
Starfish bound only to one carbohydrate site in each of the
toxin subunits, while using the remaining five Gb3 groups to
complex binding sites on a second StxB pentamer, thus holding
two pentamers together. These unexpected dimeric structures
were proposed to be thermodynamically favourable and were
thought to avoid potential strain that would arise if the ligands
were to chelate two binding sites within a single StxB protomer.
A later study indicated that divalent binding to a single StxB
protomer was accompanied by a significant entropic penalty for
restricting the dynamics of the protein.49 Improving on Starfish,
was another inhibitor from the same group nicknamed Daisy.50
This decavalent structure used the same Gb3 trisaccharide but
linked through the reducing terminus rather than two position
of the central sugar of Gb3. The new ligand with slightly longer
linker spacing between the oligosaccharide groups was found to
better protect mice against Stx-1 and Stx-2.
Fan’s group also incorporated divalent ligands into their
pentameric scaﬀolds to make the inhibitors decavalent (Fig. 8).51
Fig. 8 Star-shaped LT/CT inhibitors reported by Fan, Hol and co-workers.
Fig. 9 Star-shaped Stx inhibitors reported by Bundle and co-workers.
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These, as with the Bundle ligands, bound to two toxin pentamers
in a face to face dimer. Decavalent ligand 25 with optimised
linker lengths gave a one million-fold decrease in the IC50 value
compared to the simple monovalent ligand, again showing the
power of multivalency in these carefully designed structures.
Importantly, decavalent ligand 25 was over 10 times more
potent than the equivalent pentavalent structure 23 (n = 4).
Inhibitors using templated assembly
Templated assembly is another strategy for inducing protein
dimerisation that was pioneered by Pepys et al. in their work on
serum amyloid P component (SAP).52 SAP is a pentameric
protein in the pentraxin family that plays a role in the human
innate immune system. Pepys et al. found that simple divalent
proline derivatives e.g., 29 (Fig. 10a) are able to bring two SAP
pentamers together to form a face-to-face dimer.
SAP shares the pentameric structure that is common to
the bacterial toxins and their binding sites are conveniently
spaced for a simple divalent ligand to bridge the binding sites
in both proteins (Fig. 10b). Fan and co-workers made hetero-
divalent ligand 32 that combines a proline derivative with a
nitrophenyl galactoside and showed that it could complex
serum amyloid P component (SAP) with CTB.53 Dynamic light
scattering measurements confirmed the formation of the
two protein complex and no significant higher aggregates
were observed. Inhibition studies on CTB showed the
divalent ligand to have an IC50 of 620 mM, but when SAP was
included this value was reduced to 0.98 mM. The templating
eﬀect of the SAP protein thus provided the great enhancement
in inhibition.
In a similar way, the Bundle group have used homodivalent,
and heterodivalent ligands to create dimers of SAP54 and to
form complexes with StxB.55 In this case they employed a cyclic
ketal of pyruvate and glycerol as the SAP ligand. The flexible
short ligand 30 had an IC50 value of 3.8 mM but a more
rigid linker 31 gave a greater potency with an IC50 of 0.12 mM.
The rigid unit was thought to minimise the loss of conforma-
tional entropy upon binding. Complexes of SAP with StxB
were also formed by use of heterodivalent ligands comprising
a pyruvate acetal and the Gb3 oligosaccharide.
55 As before,
flexibility in the linker was detrimental to its inhibitory
potency; rigid ligand 33 was about 50-fold better than the more
flexible ligand 34. They found that these smaller ligands were
just as potent as the Starfish ligand in a cytotoxicity assay.
However, in vivo trials showed a poor performance for
the heterodivalent inhibitors as a consequence of their rapid
clearance when compared to the much larger Starfish
compound 26.
Heterodivalent ligands comprising a cyclic pyruvate ketal of
glycerol and the Gb3 oligosaccharide were also incorporated
onto modified a Starfish scaﬀold (Fig. 10c).56 Ligand 28 (Fig. 9),
now bifunctional, was able to bring together the two diﬀerent
proteins as expected. The inhibitor had an IC50 value of 140 mM
but in the presence of SAP this value was improved by a factor
of 35. A combination of ligand prearrangement and templating
was also demonstrated using the same heterodivalent ligands
on a polymer backbone.57 The polymers themselves had
modest inhibitory power against Stx, similar to other polymeric
inhibitors. But when combined with SAP, the protein templat-
ing eﬀect for the ligand resulted in a 100 000 fold improve-
ment on the IC50 value. These multimeric inhibitors performed
much better than Starfish 26 in a cytotoxicity assay and trials
in vivo.
Fig. 10 Templated assembly of protein dimerisation using (a) homodimeric
ligands for SAP; (b) heterodimeric ligands for SAP and StxB/LTB/CTB; (c) hetero-
dimeric ligands on a pentameric scaffold (e.g., compound 28, Fig. 9).
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Conclusions
The studies outlined in this review show us that weak interactions
can be greatly enhanced through multivalency. A wide variety of
diﬀerent structures have been created for use as multivalent
inhibitors. This article is not intended to be a comprehensive
review of all scaﬀolds investigated to date and other scaﬀolds,
e.g., calixarenes and glyconanoparticles have been discussed
elsewhere.58,59 Instead our aim has been to highlight some of
the general principles of multivalent inhibitor design for the
bacterial toxins by considering some of the major classes of
multivalent scaﬀolds. Investigations using glycopolymers and
glycodendrimers have led to the realisation that multivalent
ligands that have been designed to have an improved fit to the
carbohydrate binding sites can display a significant increase in
aﬃnity. The ligand spacing and length of spacer connecting the
sugar to the scaﬀold are important to achieve optimal binding.
However, better inhibition is not necessarily achieved bymaximising
the number of ligand groups as increased steric crowding can
prevent eﬃcient interactions from forming.
An understanding of the structure of the bacterial toxins has led
researchers tomove away from simple polymeric inhibitors tomore
sophisticated constructions. Having a prior knowledge of the target
protein is advantageous in aiding the design of the most suitable
ligands and it has been seen that prearrangement of ligands to
precisely fit the binding sites increases their inhibitory potential.
The five-fold symmetry of the toxins has directed work towards star
shaped inhibitors that present their carbohydrate ligands at precise
positions for binding. Matching the valency of the inhibitor to that
of the target protein can prevent unwanted aggregation. These
designs can be further improved by creating self-assembling
complexes of proteins. The templating eﬀect created by the first
protein can pre-organise the ligand for engaging with a second
protein molecule. Templation can also have a powerful eﬀect when
used with simple small divalent ligands. Binding interactions that
individually have unimpressive aﬃnities, can still give rise to strong
inhibition when assembling proteins.
In the search for higher aﬃnity ligands and the improved
inhibition of bacterial toxins, there are many diﬀerent multi-
valent scaﬀolds to choose from. The smartest designs, includ-
ing a combination of templating and pre-organisation of ligand
groups, have the potential to produce the most potent inhibi-
tors. Future studies should aim to combine these principles to
develop scalable, economically viable multivalent materials
that can ultimately be applied in the clinic.
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